The International Progressive MS Alliance is pleased to announce a new funding initiative designed to support innovative Experimental Medicine Trials that advance our knowledge of disease pathophysiology by defining the underlying mechanisms of an intervention, mechanisms of progressive MS pathogenesis, and/or harmonizing outcome measures that correlate with clinical efficacy for any given intervention.
The Alliance will offer an initial funding opportunity to support small Development Awards (e.g., validation studies, consensus efforts, etc.) that will result in a subsequent opportunity to apply for an Experimental Medicine Trial award. Development Awards are for planning, developmental efforts, and/or validation opportunities that support future trials. The Alliance will also accept applications for Trials that do not require Development Award support. The Alliance is interested in supporting Trials that include one or more of the following aspects:
- Use of polytherapies
- Background of immunosuppression
- Broad inclusion criteria and methodology
- Novel/alternative clinical trial designs
NOTE: The inclusion of people with MS in the development of Alliance initiatives is valuable and essential, and all proposed applications must be developed with, and informed by, perspectives of people affected by progressive MS, including trial design and execution.
Funding:
Development Award: €100,000 for 18 months
Experimental Medicine Trial: €1.5 million for up to 3 years
Important Dates:
Pre-application (Brief summary): Due 5:00 pm EDT 15 March 2024
Full application: Due 5:00 pm EDT 29 March 2024
